Home > Products > All > DOCETAXEL Injection, USP*
Product Image
Please see full prescribing and safety information, including boxed warning, for DOCETAXEL single-dose vials and multi-dose vials.

Available in:

  • 20 mg per mL single-dose vials
  • 80 mg per 4 mL single-dose vials
  • 80 mg per 8 mL multi-dose vials
  • 160 mg per 16 mL multi-dose vials

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

Downloads:

PreventIV

DOCETAXEL Injection, USP*

Brand Name Equivalent: TAXOTERE® (TAXOTERE is a registered trademark of Sanofi Mature IP.)
Therapeutic Category: Antineoplastic Agent

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
245-01 Glass Vial 20 mg 1 mL 20 mg per mL 7 mL 20 mm 1
245-04 Glass Vial 80 mg 4 mL 20 mg per mL 7 mL 20 mm 1
254-08 Glass Vial 80 mg 8 mL 10 mg per mL 10 mL 20 mm 1
254-16 Glass Vial 160 mg 16 mL 10 mg per mL 20 mL 20 mm 1
WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning
  • Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel injection concentrate at 100 mg/m² (5.1)
  • Avoid use of docetaxel if bilirubin >ULN, or if AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle (5.2)
  • Do not administer docetaxel to patients with neutrophil counts < 1500 cells/mm3. Obtain frequent blood counts to monitor for neutropenia (4, 5.3)
  • Severe hypersensitivity, including very rare fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of docetaxel injection concentrate and administration of appropriate therapy (5.5)
  • Contraindicated if history of severe hypersensitivity reactions to docetaxel injection concentrate or to drugs formulated with polysorbate 80 (4)
  • Severe fluid retention may occur despite dexamethasone (5.6)